» Articles » PMID: 26896890

Immediate Outcomes of Covered Stent Placement for Treatment or Prevention of Aortic Wall Injury Associated With Coarctation of the Aorta (COAST II)

Overview
Publisher Elsevier
Date 2016 Feb 22
PMID 26896890
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to describe the safety and short-term efficacy of the Covered Cheatham-Platinum stent (CCPS) in treating or preventing aortic wall injury (AWI) in patients with coarctation of the aorta (CoA).

Background: The COAST II trial (Covered Cheatham-Platinum Stents for Prevention or Treatment of Aortic Wall Injury Associated with Coarctation of the Aorta Trial) is a multicenter, single-arm trial using the CCPS for the treatment and/or prevention of AWI in patients with CoA and pre-existing AWI or increased risk of AWI.

Methods: Patients were enrolled if they had a history of CoA with pre-existing AWI (Treatment group) or with increased risk of AWI (Prevention group). Pre/post-implant hemodynamics and angiography were reported. A core laboratory performed standardized review of all angiograms. One-month follow-up was reported.

Results: A total of 158 patients (male = 65%; median age 19 years) underwent placement of CCPS. Eighty-three patients had pre-existing AWI. The average ascending-to-descending aorta systolic gradient improved from 27 ± 20 mm Hg to 4 ± 6 mm Hg. Complete coverage of pre-existing AWI was achieved in 66 of 71 patients (93%) with AWI who received a single CCPS. Ultimately, complete coverage of AWI was achieved in 76 of 83 patients (92%); 7 patients had minor endoleaks that did not require repeat intervention. Four patients experienced important access site vascular injury. There were no acute AWI, repeat interventions, or deaths.

Conclusions: The CCPS can effectively treat and potentially prevent AWI associated with CoA. Access site arterial injury is the most common important complication. Longer-term follow-up is necessary to define mid- and late-term outcomes.

Citing Articles

Interventions for adult congenital heart disease.

Cepas-Guillen P, Flores-Umanzor E, Horlick E, Aboulhosn J, Benson L, Freixa X Nat Rev Cardiol. 2025; .

PMID: 39833478 DOI: 10.1038/s41569-025-01118-1.


Transcatheter Interventions in Patients With Adult Congenital Heart Disease.

Tan W, Stefanescu Schmidt A, Horlick E, Aboulhosn J J Soc Cardiovasc Angiogr Interv. 2024; 1(6):100438.

PMID: 39132367 PMC: 11307551. DOI: 10.1016/j.jscai.2022.100438.


Procedural Characteristics and Outcomes of Transcatheter Interventions for Aortic Coarctation: A Report From the IMPACT Registry.

Stefanescu Schmidt A, Armstrong A, Kennedy K, Inglessis-Azuaje I, Horlick E, Holzer R J Soc Cardiovasc Angiogr Interv. 2024; 1(5):100393.

PMID: 39131475 PMC: 11308018. DOI: 10.1016/j.jscai.2022.100393.


BeGraft Aortic Stents: A European Multi-Centre Experience Reporting Acute Safety and Efficacy Outcomes for the Treatment of Vessel Stenosis in Congenital Heart Diseases.

Rebonato M, Pilati M, Milani S, Bonnet D, Pascall E, Jones M J Cardiovasc Dev Dis. 2024; 11(7).

PMID: 39057614 PMC: 11276682. DOI: 10.3390/jcdd11070192.


Different mechanisms for persistent and residual left-to-right shunt after transcatheter sinus venosus defect closure and their management.

Sagar P, Sivakumar K Ann Pediatr Cardiol. 2024; 17(1):45-51.

PMID: 38933051 PMC: 11198930. DOI: 10.4103/apc.apc_190_23.